Contributor Disclosures for Dysfibrinogenemia

Role Name Disclosure Details Author  Wendy Brick, MD, Consulting Staff, Department of Internal Medicine, Division of Hematology and Oncology, Mecklenburg Medical Group Nothing to disclose Details Coauthor  Russell Burgess, MD, Department of Internal Medicine, Division of Hematology/Oncology, East Carolina Internal Medicine Nothing to disclose Details Coauthor  Guy B Faguet, MD, Former Professor, Department of Medicine, Section of Hematology and Oncology, Medical College of Georgia Nothing to disclose Details Medical Editor  Karen Seiter, MD, Professor, Department of Internal Medicine, Division of Oncology/Hematology, New York Medical College Nothing to disclose Details Pharmacy Editor  Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine Nothing to disclose Details Managing Editor  Marcel E Conrad, MD, BS, (Retired) Distinguished Professor of Medicine, University of South Alabama No financial interests Details CME Editor  Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems Nothing to disclose Details Chief Editor  Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University Nothing to disclose Details Contributor Disclosure Contributor: Contributor Disclosure: Wendy Brick, Author  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Russell Burgess, Coauthor  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Guy B Faguet, Coauthor  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Karen Seiter, Medical Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Francisco Talavera  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication CONTRIBUTOR DISCLOSURE FORM Contributor Name: Marcel E Conrad  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** No financial interests None None   Off label or investigational use of medication None at present. I am retired. Contributor Disclosure Contributor: Contributor Disclosure: Rajalaxmi McKenna, CME Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Emmanuel C Besa  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication Revlimid in non-5q- syndrome MDSExjade in transfusion overload in MDS